Clinical Research Directory
Browse clinical research sites, groups, and studies.
SARS-CoV-2 mRNA Vaccination in Patients With Hepatocellular Carcinoma Treated With Immune Checkpoint Inhibitors
Sponsor: Medical University of Graz
Summary
A multicenter retrospective cohort analysis in Austria Primary Objective: To assess whether receiving an mRNA COVID-19 vaccine within 3 months before starting ICI (Immune checkpoint inhibitors) therapy improves best overall response (mRECIST) in HCC (hepatocellular carcinoma). Secondary Objectives: Evaluate whether vaccination within 1 or 3 months affects OS (overall survival) , PFS (Progression free survival)), or TTP (Time to progression); compare outcomes by vaccination status, vaccine type, and prior infection; explore modification by cirrhosis severity and tumor characteristics; and assess safety (irAEs, steroid use, toxicity-related discontinuation).
Official title: SARS-CoV-2 mRNA Vaccination in Patients With Hepatocellular Carcinoma Treated With Immune Checkpoint Inhibitors (CoVaCheck) A Multicenter Retrospective Cohort Analysis in Austria
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
200
Start Date
2026-01
Completion Date
2026-12
Last Updated
2026-01-14
Healthy Volunteers
No
Locations (5)
Medical University of Graz
Graz, Austria
Ordensklinikum Linz
Linz, Austria
University Hospital St. Pölten
Sankt Pölten, Austria
Krankenhaus der Barmherzigen Brüder St Veit an der Glan
Sankt Veit an der Glan, Austria
Klinikum Wels-Grieskirchen
Wels, Austria